scholarly journals Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization

2009 ◽  
Vol 6 (1) ◽  
pp. 28 ◽  
Author(s):  
Kaori Shinoda ◽  
Linda S Wyatt ◽  
Kari R Irvine ◽  
Bernard Moss
Keyword(s):  
Antibody Response ◽  
Vaccinia Virus ◽  
Neutralizing Antibody ◽  
Dna Immunization ◽  
L1 Protein

scholarly journals Screening of HIV-1 Env Glycoproteins for the Ability to Raise Neutralizing Antibody Using DNA Immunization and Recombinant Vaccinia Virus Boosting

Virology ◽  
1997 ◽  
Vol 230 (2) ◽  
pp. 265-274 ◽  
Author(s):  
J.F.L. Richmond ◽  
F. Mustafa ◽  
S. Lu ◽  
J.C. Santoro ◽  
J. Weng ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Neutralizing Antibody ◽  
Recombinant Vaccinia Virus ◽  
Dna Immunization ◽  
Recombinant Vaccinia ◽  
Hiv 1

scholarly journals The antibody response of rabbits to inactivated vaccinia virus

1965 ◽  
Vol 63 (4) ◽  
pp. 525-535 ◽  
Author(s):  
T. A. McNeill
Keyword(s):  
Antibody Response ◽  
Vaccinia Virus ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Single Factor

Inactivated vaccinia virus vaccines were prepared from purified virus inactivated by either formalin, hydroxylamine or heat. The immunogenicity of these vaccines was assessed in rabbits by measurement of virus neutralizing antibody following each of two inoculations. It was concluded that inactivated vaccinia virus stimulates the production of neutralizing antibody and that the most important single factor in this immunogenicity is the concentration of virus in the vaccine. Vaccines prepared from virus suspensions containing 107 to 108 pfu/ml. before inactivation give variable antibody responses.

scholarly journals Differential Antibody Response against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16/18 Is Observed in Vaccinated Women or with Uterine Cervical Lesions

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 442
Author(s):  
Adolfo Pedroza-Saavedra ◽  
Angelica Nallelhy Rodriguez-Ocampo ◽  
Azucena Salazar-Piña ◽  
Aislinn Citlali Perez-Morales ◽  
Lilia Chihu-Amparan ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Human Papillomavirus ◽  
Antibody Response ◽  
Roc Analysis ◽  
Neutralizing Antibody ◽  
Cervical Lesions ◽  
Serum Antibodies ◽  
Linear Epitopes ◽  
Different Populations ◽  
L1 Protein

Antibodies against the Human Papillomavirus (HPV) L1 protein are associated with past infections and related to the evolution of the disease, whereas antibodies against L1 Virus-Like Particles (VLPs) are used to follow the neutralizing antibody response in vaccinated women. In this study, serum antibodies against conformational (VLPs) and linear epitopes of HPV16/18 L1 protein were assessed to distinguish HPV-vaccinated women from those naturally infected or those with uterine cervical lesions. The VLPs-16/18 were generated in baculovirus, and L1 proteins were obtained from denatured VLPs. Serum antibodies against VLPs and L1 proteins were evaluated by ELISA. The ELISA-VLPs and ELISA-L1 16/18 assays were validated with a vaccinated women group by ROC analysis and the regression analysis to distinguish the different populations of female patients. The anti-VLPs-16/18 and anti-L1-16/18 antibodies effectively detect vaccinated women (AUC = 1.0/0.79, and 0.94/0.84, respectively). The regression analysis showed that anti-VLPs-16/18 and anti-L1-16/18 antibodies were associated with the vaccinated group (OR = 2.11 × 108/16.50 and 536.0/49.2, respectively). However, only the anti-L1-16 antibodies were associated with the high-grade lesions and cervical cancer (CIN3/CC) group (OR = 12.18). In conclusion, our results suggest that anti-VLPs-16/18 antibodies are effective and type-specific to detect HPV-vaccinated women, but anti-L1-16 antibodies better differentiate the CIN3/CC group. However, a larger population study is needed to validate these results.

scholarly journals Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets

2004 ◽  
Vol 78 (22) ◽  
pp. 12672-12676 ◽  
Author(s):  
Hana Weingartl ◽  
Markus Czub ◽  
Stefanie Czub ◽  
James Neufeld ◽  
Peter Marszal ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Severe Acute Respiratory Syndrome ◽  
Antibody Response ◽  
Vaccinia Virus ◽  
Inflammatory Responses ◽  
Neutralizing Antibody ◽  
Mustela Putorius ◽  
S Protein ◽  
Modified Vaccinia Virus Ankara ◽  
Human Infectious Disease

ABSTRACT Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) is a serious emerging human infectious disease. In this report, we immunized ferrets (Mustela putorius furo) with recombinant modified vaccinia virus Ankara (rMVA) expressing the SARS-CoV spike (S) protein. Immunized ferrets developed a more rapid and vigorous neutralizing antibody response than control animals after challenge with SARS-CoV; however, they also exhibited strong inflammatory responses in liver tissue. Inflammation in control animals exposed to SARS-CoV was relatively mild. Thus, our data suggest that vaccination with rMVA expressing SARS-CoV S protein is associated with enhanced hepatitis.

scholarly journals Recombinant Modified Vaccinia Virus Ankara Expressing the Surface gp120 of Simian Immunodeficiency Virus (SIV) Primes for a Rapid Neutralizing Antibody Response to SIV Infection in Macaques

2000 ◽  
Vol 74 (6) ◽  
pp. 2960-2965 ◽  
Author(s):  
Ilnour Ourmanov ◽  
Miroslawa Bilska ◽  
Vanessa M. Hirsch ◽  
David C. Montefiori
Keyword(s):  
Antibody Response ◽  
Vaccinia Virus ◽  
Simian Immunodeficiency Virus ◽  
Neutralizing Antibodies ◽  
Rhesus Macaques ◽  
Neutralizing Antibody ◽  
Anamnestic Response ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus ◽  
Before And After

ABSTRACT Neutralizing antibodies were assessed before and after intravenous challenge with pathogenic SIVsmE660 in rhesus macaques that had been immunized with recombinant modified vaccinia virus Ankara expressing one or more simian immunodeficiency virus gene products (MVA-SIV). Animals received either MVA-gag-pol, MVA-env, MVA-gag-pol-env, or nonrecombinant MVA. Although no animals were completely protected from infection with SIV, animals immunized with recombinant MVA-SIV vaccines had lower virus loads and prolonged survival relative to control animals that received nonrecombinant MVA (I. Ourmanov et al., J. Virol. 74:2740–2751, 2000). Titers of neutralizing antibodies measured with the vaccine strain SIVsmH-4 were low in the MVA-env and MVA-gag-pol-env groups of animals and were undetectable in the MVA-gag-pol and nonrecombinant MVA groups of animals on the day of challenge (4 weeks after final immunization). Titers of SIVsmH-4-neutralizing antibodies remained unchanged 1 week later but increased approximately 100-fold 2 weeks postchallenge in the MVA-env and MVA-gag-pol-env groups while the titers remained low or undetectable in the MVA-gag-pol and nonrecombinant MVA groups. This anamnestic neutralizing antibody response was also detected with T-cell-line-adapted stocks of SIVmac251 and SIV/DeltaB670 but not with SIVmac239, as this latter virus resisted neutralization. Most animals in each group had high titers of SIVsmH-4-neutralizing antibodies 8 weeks postchallenge. Titers of neutralizing antibodies were low or undetectable until about 12 weeks of infection in all groups of animals and showed little or no evidence of an anamnestic response when measured with SIVsmE660. The results indicate that recombinant MVA is a promising vector to use to prime for an anamnestic neutralizing antibody response following infection with primate lentiviruses that cause AIDS. However, the Env component of the present vaccine needs improvement in order to target a broad spectrum of viral variants, including those that resemble primary isolates.

scholarly journals Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

2021 ◽  
Author(s):  
Kanika Vanshylla ◽  
Veronica Di Cristanziano ◽  
Franziska Kleipass ◽  
Felix Dewald ◽  
Philipp Schommers ◽  
...  
Keyword(s):  
Antibody Response ◽  
Neutralizing Antibody

scholarly journals SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Nanda Kishore Routhu ◽  
Narayanaiah Cheedarla ◽  
Venkata Satish Bollimpelli ◽  
Sailaja Gangadhara ◽  
Venkata Viswanadh Edara ◽  
...  
Keyword(s):  
Antibody Response ◽  
Antibody Titer ◽  
Neutralizing Antibodies ◽  
Rhesus Macaques ◽  
Neutralizing Antibody ◽  
Significant Loss ◽  
Lung Pathology ◽  
Live Virus ◽  
Suitable Candidate ◽  
Immune Pathology

AbstractThere is a great need for the development of vaccines that induce potent and long-lasting protective immunity against SARS-CoV-2. Multimeric display of the antigen combined with potent adjuvant can enhance the potency and longevity of the antibody response. The receptor binding domain (RBD) of the spike protein is a primary target of neutralizing antibodies. Here, we developed a trimeric form of the RBD and show that it induces a potent neutralizing antibody response against live virus with diverse effector functions and provides protection against SARS-CoV-2 challenge in mice and rhesus macaques. The trimeric form induces higher neutralizing antibody titer compared to monomer with as low as 1μg antigen dose. In mice, adjuvanting the protein with a TLR7/8 agonist formulation alum-3M-052 induces 100-fold higher neutralizing antibody titer and superior protection from infection compared to alum. SARS-CoV-2 infection causes significant loss of innate cells and pathology in the lung, and vaccination protects from changes in innate cells and lung pathology. These results demonstrate RBD trimer protein as a suitable candidate for vaccine against SARS-CoV-2.

Sign in / Sign up

Export Citation Format

Share Document